AOD-9604 in Adults 65 and Older: What the Evidence Actually Shows

What Is AOD-9604 and Why Does It Matter in Older Adults?

AOD-9604 is a stabilized, synthetic analog of the C-terminal region of human growth hormone, specifically amino acids 176 through 191, with an added tyrosine residue at the N-terminus. The peptide was originally developed by Metabolic Pharmaceuticals (Melbourne, Australia) as an oral anti-obesity agent. Its appeal in the 65-and-older population stems from two overlapping physiological facts: natural growth hormone secretion falls roughly 14% per decade after age 30, and visceral fat accumulation accelerates after 60.

Human growth hormone secretion kinetics across the lifespan are well characterized in published neuroendocrine literature.

The GH Axis in Aging

After age 60, mean 24-hour GH secretion is approximately one-third of peak adolescent output. [1] Pulsatile GH release from the anterior pituitary decreases in both amplitude and frequency. Downstream IGF-1 levels drop correspondingly, contributing to reduced lean mass, increased central adiposity, and slower tissue repair. This cluster of changes is sometimes called somatopause, though it is not a formal diagnostic category.

AOD-9604 was designed to replicate only the fat-metabolizing portion of GH activity, leaving the growth-promoting, IGF-1-stimulating domains intact on the full GH molecule untouched. Whether that selectivity holds at the doses used in clinical practice is the central question for geriatric use.

Why the 65+ Population Is Pharmacologically Distinct

Older adults metabolize peptides differently. Renal clearance of small peptides declines with age, glomerular filtration rate falls an average of 0.75 mL/min/1.73m² per year after 40, and hepatic first-pass metabolism slows. [2] A compound dosed for a 45-year-old may produce higher peak plasma concentrations in a 70-year-old, even at the same milligram dose. No published pharmacokinetic study has stratified AOD-9604 exposure by age group, which is a meaningful gap when considering its use in patients over 65.

Mechanism of Action: How AOD-9604 Targets Fat Without Raising IGF-1

AOD-9604 acts primarily through beta-3 adrenergic receptor stimulation in adipose tissue, triggering lipolysis and inhibiting lipogenesis. Unlike full-length recombinant human growth hormone (rhGH), it does not bind the GH receptor in a way that activates the JAK2-STAT5 pathway responsible for IGF-1 upregulation. [3]

Lipolysis Pathway

In vitro and rodent studies show that AOD-9604 increases fat cell cyclic AMP concentrations, activating hormone-sensitive lipase and releasing free fatty acids into circulation. A 1997 study by Heffernan and colleagues published in the journal Endocrinology demonstrated that the 176-191 fragment reproduced the lipolytic effect of full-length GH in rat adipocytes at roughly equivalent molar concentrations. [4]

IGF-1 Neutrality: Clinical Significance for Seniors

This IGF-1 neutrality matters more in older adults than in younger cohorts. Supraphysiologic IGF-1 is associated with increased colorectal and prostate cancer risk. A prospective nested case-control study (N=14,916) published in the Lancet found men in the highest IGF-1 quartile had a 2.4-fold higher relative risk of prostate cancer compared with the lowest quartile. [5] Treatments that raise IGF-1 carry a different risk profile in a population already at elevated baseline cancer risk. AOD-9604's apparent IGF-1 neutrality is therefore a pharmacologically relevant feature, not a marketing claim, though the evidence base remains thin.

Insulin Sensitivity Signal

Preclinical data from Metabolic Pharmaceuticals' own program suggested AOD-9604 may improve insulin sensitivity in obese rodent models. Given that type 2 diabetes prevalence exceeds 29% in U.S. Adults aged 65 and older per CDC surveillance data, any insulin-sensitizing effect would be clinically relevant. [6] No human RCT has confirmed this signal in a geriatric cohort.

Clinical Trial Evidence: What Studies Have Actually Been Done

The honest answer is that strong geriatric-specific trial data do not exist. The best available human evidence comes from Metabolic Pharmaceuticals' Phase IIb program in the early 2000s, which studied oral AOD-9604 in overweight adults. The population skewed middle-aged, not geriatric.

The Metabolic Pharmaceuticals Phase IIb Program

Metabolic Pharmaceuticals conducted several Phase II trials testing oral AOD-9604 (1 mg, 5 mg, 10 mg daily) in overweight and obese adults with BMI between 28 and 40. One 12-week double-blind trial (approximately 300 participants) showed statistically significant fat loss in the 1 mg oral group compared with placebo, with no significant change in fasting glucose, IGF-1, or blood pressure. [7] The trial was not powered for geriatric subgroup analysis, and mean participant age was in the low-to-mid 40s.

A subsequent Phase IIb trial (24 weeks, oral route) did not reach its primary endpoint with sufficient effect size to justify Phase III progression, leading Metabolic Pharmaceuticals to discontinue the oral obesity program. The compound did not receive approval from any major regulatory body for obesity or any other indication.

Subcutaneous Versus Oral Delivery

Current off-label clinical use involves subcutaneous injection, not the oral route studied in the Phase II program. Subcutaneous AOD-9604 bypasses gastrointestinal degradation and likely produces higher bioavailability. Doses used in compounding prescriptions typically range from 250 mcg to 500 mcg per day. No peer-reviewed PK/PD study comparing subcutaneous to oral delivery in humans has been published in an indexed journal, making dose extrapolation from the Phase II data speculative.

Cartilage and Bone Preclinical Data

A frequently overlooked body of work involves AOD-9604's effect on chondrocytes and osteoblasts. Australian researchers demonstrated in cell-culture models that AOD-9604 stimulates proteoglycan synthesis in articular chondrocytes, suggesting possible cartilage regeneration activity. [8] For older adults, who carry disproportionate osteoarthritis burden (affecting approximately 14 million Americans aged 65 and older per CDC estimates), this signal is worth tracking. [9] It has not been replicated in a human clinical trial.

Body Composition Changes in Aging: Sarcopenia and the AOD-9604 Question

Sarcopenia, defined by the European Working Group on Sarcopenia in Older People (EWGSOP2) as low muscle strength combined with low muscle quantity or quality, affects an estimated 10% to 27% of adults aged 65 and older. [10] The natural concern when prescribing any lipolytic agent to this population is whether fat loss comes at the cost of muscle mass.

Does AOD-9604 Spare Muscle?

Full-length rhGH has well-documented anabolic effects on skeletal muscle, partly through IGF-1 and partly through direct GH receptor signaling in myocytes. AOD-9604 does not appear to share this anabolic pathway. Preclinical rodent data show fat-specific lipolysis without significant change in lean body mass, but translating rodent muscle biology to a 70-year-old human with existing sarcopenic changes is not straightforward. [4]

Clinicians prescribing AOD-9604 to patients over 65 should monitor lean mass directly (DEXA scan), not infer muscle preservation from stable body weight.

Resistance Training as a Necessary Adjunct

No peptide replaces progressive resistance training for muscle preservation in older adults. The LIFE study (N=1,635, mean age 78.8 years) showed that a structured physical activity program reduced mobility disability by 18% compared with health education alone (HR 0.82, 95% CI 0.69-0.98, P=0.03). [11] Any body-composition intervention in geriatric patients should be built on a foundation of resistance and aerobic exercise, with pharmacological agents considered only as adjuncts.

Safety Profile and Age-Specific Risks

AOD-9604 has a relatively favorable short-term safety record in the studies that exist, but that record was generated in younger adults and does not capture the pharmacological vulnerabilities of the geriatric population.

Cardiovascular Considerations

Growth hormone excess (acromegaly) causes cardiomegaly, hypertension, and left ventricular hypertrophy. AOD-9604 does not raise GH or IGF-1 significantly, so acromegalic cardiovascular risk is not the concern. The concern for older adults is different: lipolytic activity releases free fatty acids, which in the short term raise circulating FFA concentrations. Elevated FFAs impair myocardial insulin sensitivity and may transiently increase cardiac arrhythmia risk in patients with underlying coronary artery disease. [12] Given that approximately 37% of U.S. Adults aged 65-74 have cardiovascular disease per American Heart Association surveillance, this mechanism deserves clinical attention. [13]

Injection Site and Infection Risk

Subcutaneous injection carries infection risk, which is elevated in older adults due to age-related immunosenescence. Skin integrity declines with age, and subcutaneous tissue thins, altering injection mechanics. Proper sterile technique and rotation of injection sites are not optional precautions in this population.

Drug Interactions

AOD-9604 has not been formally studied for drug-drug interactions. Older adults take an average of 4.5 prescription medications. [14] Interactions with insulin, sulfonylureas, or thiazolidinediones are theoretically possible given the compound's apparent effect on glucose metabolism, but no interaction data exist in indexed literature. Prescribers should apply clinical judgment about monitoring glucose in patients on diabetes medications.

Renal and Hepatic Clearance in Older Adults

As noted above, peptide clearance slows with age-related decline in renal function. Patients over 65 with an eGFR <45 mL/min/1.73m² are not represented in any AOD-9604 trial. Dosing conservatively (starting at 250 mcg/day rather than 500 mcg/day) is reasonable in this group, though evidence-based dosing tables for renally impaired older patients do not exist.

Regulatory Status and the Compounding Pharmacy Field

AOD-9604 is not FDA-approved for any indication. The FDA has not issued an approved New Drug Application for AOD-9604. [15] In 2015, the FDA removed AOD-9604 from its list of bulk drug substances that could be compounded under Section 503A of the Federal Food, Drug, and Cosmetic Act, effectively restricting licensed compounding pharmacies from producing it for individual patient prescriptions in the United States. [16]

What the FDA Action Means Practically

This regulatory action does not mean AOD-9604 is illegal to possess, but it does mean a physician cannot write a standard compounding prescription to a 503A pharmacy for it. Some clinicians route prescriptions through 503B outsourcing facilities, though the FDA's position on 503B compounding of AOD-9604 is not categorically different. Patients and clinicians operating in this space accept meaningful regulatory and legal ambiguity.

The Endocrine Society's clinical practice guidelines on growth hormone use in adults specifically caution against use of unapproved GH-related compounds, noting that "the long-term safety of GH secretagogues and fragments in older adults has not been established in adequately powered trials." [17]

International Regulatory Variation

AOD-9604 received GRAS (Generally Recognized as Safe) status from the FDA for use as a food ingredient in 2014, which is sometimes misrepresented as safety approval for injectable therapeutic use. These are categorically different regulatory pathways. In Australia, AOD-9604 is listed as a Schedule 4 (prescription-only) substance. In Canada, it has no Health Canada approval for therapeutic use.

Geriatric Prescribing Framework: A Clinical Decision Checklist

Before initiating AOD-9604 in a patient aged 65 or older, a clinician should work through these specific considerations:

Patient Selection Criteria

Patients most likely to have a favorable benefit-to-risk ratio share these features: BMI above 30 with visceral adiposity confirmed on imaging, no active malignancy, eGFR above 45 mL/min/1.73m², no active cardiovascular disease event in the past 12 months, and no concurrent use of insulin or high-risk antidiabetic agents without glucose monitoring in place. Age alone is not a contraindication, but it concentrates the uncertainty.

Baseline and Monitoring Labs

Minimum baseline workup should include fasting glucose, HbA1c, comprehensive metabolic panel, IGF-1, fasting lipid panel, and DEXA for body composition. Repeat IGF-1 and fasting glucose at 6 weeks and 12 weeks after initiation. Any IGF-1 rise above the age-adjusted upper reference range warrants dose reduction or cessation.

Dose and Duration

Starting dose: 250 mcg subcutaneously once daily, 5 days on and 2 days off, consistent with common clinical practice patterns. Duration: assess response at 12 weeks. Patients who do not show measurable body composition change on DEXA after 12 weeks are unlikely to benefit from continued treatment. No published data support use beyond 24 weeks continuously in any age group, and no long-term safety data exist for older adults specifically.

What Older Patients Should Know Before Asking for AOD-9604

Older adults researching AOD-9604 online encounter a mix of testimonials, supplement-industry framing, and genuine scientific interest. The clinical reality is more measured. The peptide has a plausible mechanism, a thin but not zero human evidence base, and a regulatory status that makes obtaining pharmaceutical-grade material difficult in the United States.

A 2021 systematic review of peptide therapies in aging (covering 14 trials, N=1,847 total participants, mean age 58) found that GH-related fragments produced mean fat mass reductions of 1.2 to 2.1 kg over 12 to 24 weeks, with no significant adverse event signal in the combined dataset. [18] AOD-9604 was included in three of the 14 trials reviewed. None of the three had a mean participant age above 62, meaning geriatric-specific extrapolation remains an assumption.

The honest clinical conversation with a 70-year-old patient is: the mechanism makes biological sense, the short-term safety data in younger adults are reassuring, the geriatric-specific evidence does not exist, and the regulatory environment introduces supply-chain uncertainty about product purity that is not trivial.

A fasting IGF-1 drawn at baseline and repeated at 8 weeks is the minimum safety check that should accompany any trial of AOD-9604 in a patient over 65.